Recent Updates
Recently added Catalysts
ETON Positive Sentiment Score: 60/100

Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Tuesday, August 1, 2023 2 min read
Key Takeaway: Eton Pharmaceuticals, Inc. will report its second quarter 2023 financial results on August 10, 2023. A conference call and live audio webcast will be held at 4:30 p.m. ET to discuss the results, where management will also engage with investors through live questions and emails. The company is actively developing treatments for rare diseases and currently has three FDA-approved products.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals is focused on developing treatments for rare diseases.
  • The company has three FDA-approved products.
  • Management is engaging with investors through live Q&A sessions.

Full Press Release Details

DEER PARK, Ill., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2023 financial results on Thursday, August 10, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Register* (Audio Only) Click here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
* Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has three FDA-approved products in ALKINDI SPRINKLE®, Carglumic Acid tablets, and Betaine Anhydrous for oral solution, and four late-stage pipeline candidates under development with dehydrated alcohol injection, ZENEO® hydrocortisone autoinjector, ET-400, and ET-600. In addition, the Company receives royalties and is entitled to receive milestone payments on other products. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals

Frequently Asked Questions

When will Eton Pharmaceuticals report its Q2 2023 financial results?

Eton Pharmaceuticals will report its Q2 2023 financial results on August 10, 2023.

What time is the Eton Pharmaceuticals conference call?

The conference call will be held at 4:30 p.m. ET on August 10, 2023.

How can investors submit questions during the call?

Investors can submit questions via email to investorrelations@etonpharma.com.

Where can I access the live webcast of the conference call?

The live webcast can be accessed on Eton's Investors webpage.

What are some products developed by Eton Pharmaceuticals?

Eton has FDA-approved products like ALKINDI SPRINKLE® and Carglumic Acid tablets.

Tags: ETON Viatris Investor Conferences Healthcare Eton Pharmaceuticals Q2 2023 financial results FDA-approved products rare diseases investor relations
Last updated: Aug 1, 2023